Skip to main content
Premium Trial:

Request an Annual Quote

IntegraGen, Pompidou Hospital to Develop Sequencing Methods

NEW YORK (GenomeWeb) – IntegraGen and the Georges Pompidou European Hospital (HEGP) today announced an agreement to develop high-throughput sequencing methods. 

Clinicians and biologists at the hospital will use the new methods along with bioinformatic analysis techniques jointly developed by the partners in order to rapidly interpret genomic data. The technologies will enable patients, particularly those with cancer tumors, to be rapidly prescribed targeted therapies, IntegraGen and HEGP said. 

The deal will allow oncologists and biologists at Paris-based HEGP to "benefit from the latest genome sequencing technologies and … to develop specific tools for interpreting results which enable the personalized care of patients," Pierre Laurent-Puig, an oncology biologist at the hospital, said in a statement. "This will result in a better ability to diagnose and treat each patient on an individual basis, depending on the genetic markers identified in their tumor." 

HEGP operates under the aegis of the public hospital system of the city of Paris and its suburbs.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.